Human Anti-HIV-1 Recombinant Antibody (clone VRC26.25)
CAT#: PABL-140
Recombinant Human Antibody (VRC26.25) is capable of binding to HIV-1, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody neutralized 57% of diverse clade 43 viral isolates and 70% of clade C isolates with remarkable potency.
Published Data
Tested Data
Figure 1 Neutralization profiles of PGDM1400 and CAP256-VRC26.25 against a multi-clade panels of 208 pseudoviruses (A) and highlighting specifically the activity of both bNAbs against clade C pseudoviruses (B).
(A) Each bar represents the IC80 (μg/ml) of PGDM1400 (upper graph) or CAP256-VRC26.25 (lower graph) against a single virus. Viruses are ranked according to increasing IC80 values. Bars reaching the dotted line represent IC80 values>50 μg/mL. The red bars highlight the IC80 values for PGDM1400 (upper graph) or CAP256-VRC26.25 (lower graph) against SHIV-325c. (B) IC80 values for PGDM1400 and CAP256-VRC26.25 against SHIV-325c (red dot) and against the clade C pseudoviruses included in panel (A). The horizontal bars represent the mean of IC80 values of neutralizable pseudoviruses.
Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.
Figure 2 Neutralization of SHIV-325c by CAP256-VRC26.25, PGDM1400 and PG9
Neutralization was measured using replication competent challenge stock SHIV-325c infection of TZM-bl cells. All 3 antibodies showed 100% neutralization of SHIV-325c with no evidence of a plateau effect below 100% neutralization.
Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.
Figure 3 Protective efficacy of PGDM1400 and CAP256-VRC26.25-LS against SHIV-325c in rhesus macaques
Plasma viral RNA (log RNA copies/mL) are shown for animals that received placebo control (A), 2 mg/kg PGDM1400 (B), 0.4 mg/kg PGDM1400 (C), 0.08 mg/kg PGDM1400 (D), 2 mg/kg CAP256-VRC26.25-LS (E), 0.4 mg/kg CAP256-VRC26.25-LS (F), or 0.08 mg/kg CAP256-VRC26.25-LS (G). All placebo controls became infected. Protection was observed in all animals that received CAP256-VRC26.25-LS at all doses. 1/5 animals in the PGDM1400 2 mg/kg dose group and 3/4 animals in the 0.08 mg/kg PGDM1400 dose group were infected. The assay sensitivity limit was>50 RNA copies/mL.
Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.
Figure 4 Serum concentration of CAP256-VRC26.25-LS and PGDM1400 in antibody treated animals
bNAb concentrations were determined by ELISA. The results show average serum concentrations of 19.8 μg/ml, 3.3 μg/ml and 0.75 μg/mL on the day of challenge in the CAP256-VRC26.25-LS 2 mg/kg, 0.4 mg/kg and 0.08 mg/kg groups, respectively, and 6.9 μg/mL, 2.5 μg/mL and 0.22 μg/mL on the day of challenge in the PGDM1400 2 mg/kg, 0.4 mg/kg and 0.08 mg/kg groups, respectively.
Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.
❮
❯
SDS-PAGE
Figure 1 Anti-HIV-1 Recombinant Antibody (PABL-140) in SDS-PAGE
SDS-PAGE analysis of PABL-140 in non-reduced (Lane 1) and reduced (Lane 2) conditions.
SEC-HPLC
Figure 2 Anti-HIV-1 Recombinant Antibody (PABL-140) in HPLC
The purity of PABL-140 was greater than 95% as determined by HPLC.
❮
❯
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Type
- Human IgG1
- Specificity
- Tested positive against HIV-1 HIV-1
- Species Reactivity
- HIV-1
- Clone
- VRC26.25
- Applications
- WB, ELISA, Neut, FuncS
Product Property
- Purity
- >95% as determined by SDS-PAGE
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Applications
- Application Notes
- Neutralization of diverse, replication-competent SHIV challenge stocks (including SHIV-325c) or Env-pseudoviruses was evaluated in vitro by using TZM-bl target cells and a luciferase reporter assay. Briefly, HIV-1 Env pseudoviruses were generated by transfection in 293T cells, and SHIV challenge stocks were produced by transfection of 293T cells with infectious molecular clone plasmids, followed by propagation in human or rhesus PBMC. The rhesus PBMC derived stock of SHIV-AD8 was kindly provided by Dr. Malcolm Martin and SHIV-1157ipd3N4 was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. Ruth Ruprecht. SHIV stocks or HIV-1 pseudoviruses were incubated with the antibody for 30 min at 37°C before TZM-bl cells were added. The protease inhibitor indinavir was added to assays with SHIV stocks to a final concentration of 1 μM to limit infection of target cells to a single round of viral replication. Luciferase expression was quantified 48 h after infection upon cell lysis and the addition of luciferin substrate (Promega).
Target
- Alternative Names
- HIV-1; human immunodeficiency virus
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for PABL-140. Click the button above to contact us or submit your feedback about this product.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "Clone VRC26.25"
- CAT
- Product Name
See other products for "HIV-1"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NAB-1889-sdAb | Recombinant Anti-HIV-1 VHH Single Domain Antibody | WB, ICC, ChiP, FA, ELISA | Llama VHH |
| PNBL-038 | Recombinant Anti-HIV-1 C186 gp120 VHH Single Domain Antibody (PNBL-038) | WB, FuncS | Llama VHH |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-068 | Anti-HIV-1 Recombinant Antibody (TAB-068) | WB, ELISA, IP, FC, FuncS, Neut, IF | IgG1 - kappa |
| PABX-094-S (P) | Recombinant Human Anti-HIV-1 Antibody scFv Fragment (Fab4025) | WB, ELISA, FuncS | scFv |
| PABX-099-S (P) | Recombinant Human Anti-HIV-1 Antibody scFv Fragment | FC, FuncS | scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AGTO-G037E | Anti-HIV-1 immunotoxin 3B3 (scFv)-PE | Cytotoxicity assay, Function study | |
| AGTO-G037D | Anti-HIV-1 immunotoxin 3B3 (scFv)-DT | Cytotoxicity assay, Function study |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PFBL-140 | Human Anti-HIV-1 Recombinant Antibody (clone VRC26.25); Fab Fragment | WB, ELISA, Neut, FuncS | Human Fab |
| HPAB-0158-YJ-F(E) | Human Anti-HIV-1 Recombinant Antibody; Fab Fragment (HPAB-0158-YJ-F(E)) | ELISA, Neut, Inhib | Human Fab |
| HPAB-AP363-YC-F(E) | Human Anti-HIV-1 Recombinant Antibody (clone A2); Fab Fragment | ELISA, Neut | Human Fab |
| HPAB-1988-FY-F(E) | Human Anti-HIV-1 Recombinant Antibody (clone 2G9); Fab Fragment | FC, ELISA | Human Fab |
| HPAB-1989-FY-F(E) | Human Anti-HIV-1 Recombinant Antibody (clone 9F11); Fab Fragment | FC, ELISA | Human Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABX-001-S (P) | Recombinant Human Anti-HIV-1 Antibody scFv Fragment (1281) | WB, FuncS | scFv |
| PABX-008-F (E) | Recombinant Mouse Anti-HIV-1 Antibody Fab Fragment | WB, IHC, IF, FuncS | Fab |
| PABX-084-F (E) | Recombinant Mouse Anti-HIV-1 Antibody Fab Fragment (83.1) | WB, ELISA, FuncS | Fab |
| PABX-089-F (E) | Recombinant Mouse Anti-HIV-1 Antibody Fab Fragment (A10F9) | Neut, FuncS | Fab |
| PABX-093-F (E) | Recombinant Mouse Anti-HIV-1 Antibody Fab Fragment (Fab28) | WB, ELISA, FuncS | Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABX-093-S (P) | Recombinant Mouse Anti-HIV-1 Antibody scFv Fragment (Fab28) | WB, ELISA, FuncS | scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABX-001-F (E) | Recombinant Human Anti-HIV-1 Antibody Fab Fragment (1281) | WB, FuncS | Fab |
| PABX-087-F (E) | Recombinant Human Anti-HIV-1 Antibody Fab Fragment (2G12) | WB, ELISA, FuncS | Fab |
| PABX-088-F (E) | Recombinant Human Anti-HIV-1 Antibody Fab Fragment (447-52D) | WB, ELISA, IF, FuncS | Fab |
| PABX-090-F (E) | Recombinant Human Anti-HIV-1 Antibody Fab Fragment (CH04H/CH02L) | Neut, FuncS | Fab |
| PABX-091-F (E) | Recombinant Human Anti-HIV-1 Antibody Fab Fragment (Fab2219) | Neut, ELISA, FuncS | Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MHC-LC1376 | PE-A*02:01/HIV-1 (SLFNTVATL) MHC Tetramer | FCM | |
| MHC-LC1377 | APC-A*02:01/HIV-1 (SLFNTVATL) MHC Tetramer | FCM | |
| MHC-LC1378 | BV421-A*02:01/HIV-1 (SLFNTVATL) MHC Tetramer | FCM |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOR-4221 | Rabbit Anti-HIV-1 Recombinant Antibody (clone SI300DS) | ELISA, ICC, IF, FC | Rabbit IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| FAMAB-0176CQ-S(P) | Mouse Anti-HIV-1 Recombinant Antibody (clone KEL10); scFv Fragment | ELISA, Neut | Mouse scFv |
| HPAB-0158-YJ-S(P) | Mouse Anti-HIV-1 Recombinant Antibody; scFv Fragment (HPAB-0158-YJ-S(P)) | ELISA, Neut, Inhib | Mouse scFv |
| HPAB-AP363-YC-S(P) | Human Anti-HIV-1 Recombinant Antibody (clone A2); scFv Fragment | ELISA, Neut | Human scFv |
| HPAB-1988-FY-S(P) | Human Anti-HIV-1 Recombinant Antibody (clone 2G9); scFv Fragment | FC, ELISA | Human scFv |
| HPAB-1989-FY-S(P) | Human Anti-HIV-1 Recombinant Antibody (clone 9F11); scFv Fragment | FC, ELISA | Human scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AFC-TAB-068 | Afuco™ Anti-HIV-1 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-068) | ELISA, IP, FC, FuncS, Neut | ADCC enhanced antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-AP363-YC | Human Anti-HIV-1 Recombinant Antibody (clone A2) | FuncS, FC | Human IgG |
| VS-0423-XY8 | Mouse Anti-HIV-1 Recombinant Antibody (clone CP503) | ELISA | Mouse IgG |
| VS-0423-XY9 | Mouse Anti-HIV-1 Recombinant Antibody (clone CP506) | ELISA | Mouse IgG |
| VS-0423-XY10 | Mouse Anti-HIV-1 Recombinant Antibody (clone CP507) | ELISA | Mouse IgG |
| VS-0423-XY28 | Human Anti-HIV-1 Recombinant Antibody (clone sb1) | ELISA | Human IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-1988-FY | Human Anti-HIV-1 Recombinant Antibody (clone 2G9) | FC, ELISA, Neut | Human IgM |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0125-FY67 | Human Anti-HIV-1 (clone 3D6) scFv-Fc Chimera | Neut | Human IgG1, scFv-Fc |
| VS-0125-FY68 | Human Anti-HIV-1 (clone 2F5) scFv-Fc Chimera | Neut | Human IgG1, scFv-Fc |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: Neut, ELISA, IF, IP, FuncS, FC, IHC
Application: ELISA, IP, FC, FuncS, Neut, IF, WB
Application: FuncS, IF, Neut, ELISA, FC, IP, IHC
Application: WB, ELISA, FuncS, IB, FC, SPR, Apop
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA
Application: WB, FC, IF, Inhib, ELISA, IHC
Application: ELISA, Vaccine, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
